Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 203a (miR-203a) is a small, non-coding RNA of approximately 22 nucleotides, belonging to the microRNA class, with a locus at chromosome 14q32.33[5]. It exerts its function primarily through the post-transcriptional regulation of gene expression by binding to target mRNAs and repressing their translation or promoting degradation[5]. miR-203a acts as a tumor suppressor in several malignancies, including breast cancer, by inhibiting cell cycle progression, proliferation, migration, and by promoting apoptosis, frequently through interactions with genes like PIK3CA, Wnt2b, BMI1, WT1, and XIAP[1][3]. Its expression and methylation status have diagnostic and prognostic utility in various cancers and it has been investigated as a molecular biomarker[2][3][4][5]. There are no clinically approved drugs that directly target miR-203a, but it is being explored as an intervention point in experimental and preclinical tumor gene therapy research[3][5].
Regulation by inhibition of translation or degradation of specific mRNA targets involved in oncogenic signaling (e.g., targeting PIK3CA, Wnt2b, BMI1, WT1, XIAP, BIRC5, LASP1)[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 203a (miR-203a).